Climb Bio, Inc. Common Stock
CLYMStock
$12.58+832.39%52W
Market Cap$794.24M
P/E—
Div yield—
Beta0.10
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)238.83%
Price vs S&P 500 (4W)15.63%
VGM Score88.44
Market Capitalization$794.24M
Earnings Surprise History
Q1 26-0.20est. -0.27
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.44
4.42
4.40
4.43
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLYMClimb Bio, Inc. Common Stock | — | — | A | $12.58 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete B cells for the treatment of B-cell-mediated diseases.